MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2026 International Congress

    High-dimensional proteomic profiling in plasma and CSF identifies molecular signatures in Parkinson’s disease

    S. Rota, B. Batzu, M. Veronese, J. Shubert, A. Heslegrave, B. Fernandes Gomes, A. Reith, C. Parker, S. Lee, N. Barwick, S. Williams (London, United Kingdom)

    Objective: To characterise Parkinson’s disease (PD)-related proteomic profiles in plasma and cerebrospinal fluid (CSF), to assess differential expression between PD and healthy controls (HC), along…
  • 2026 International Congress

    Global Performance Patterns in the MDS-UPDRS Motor Certification Program: A five-year Analysis

    C. Falup-Pecurariu, C. Akbostanci, E. Bayram, I. Estrada-Bellmann, J. Ma, T. Mestre, I. Murasan, O. Ojo, P. Pal, M. Qamar, F. Rodriguez-Porcel, A. Sanchez Ferro (Brasov, Romania)

    Objective: To evaluate participation trends, certification rates, case-level difficulty, and item-level performance patterns over five years. Background: The MDS-UPDRS Part III is a core outcome…
  • 2026 International Congress

    Foslevodopa-Foscarbidopa Continuous Subcutaneous Infusion Leads to Long-Term Reduction in Dyskinesia in Parkinson’s Disease: Results from 5-Year Follow-Up

    N. Jeyakumar, P. Becker, M. Georgiades, D. Tsui, X. Chen, S. Bray, J. Qiu, S. Waller, L. Williams, S. Dal, T. Ong, A. Martin, H. Morales-Briceno, V. Fung (Sydney, Australia)

    Objective: To investigate the long-term impact of foslevodopa-foscarbidopa continuous subcutaneous infusion (CSCI) on dyskinesia in Parkinson’s disease (PD). Background: Foslevodopa-foscarbidopa CSCI is an emerging treatment…
  • 2026 International Congress

    Creutzfeldt Jakob Disease Miming a Cortico-basal syndrome: does it exist?

    Y. Memmich, R. Zouari, D. Bn Mohamed, Z. Saied, A. Rachdi, F. Nabli, S. Ben Sassi (tunis, Tunisia)

    Objective: Our objective is to report a rare and unusual association and assess the plausibility of sporadic Creutzfeldt‑Jakob disease as an underlying cause of corticobasal…
  • 2026 International Congress

    Shared and Sex-Specific Genetic Risk for Parkinson’s Disease Across European Populations

    H. Leonard, M. Makarious, L. Lange, P. Reyes-Pérez, A. Singleton, C. Blauwendraat (Wasington, USA)

    Objective: To investigate sex-specific autosomal genetic factors associated with PD risk. Background: Parkinson’s disease (PD) affects females and males differently, with differences in prevalence, clinical…
  • 2026 International Congress

    Disentangling Disease- and Medication-Associated Gut Microbiome Signatures in Parkinson’s Disease

    MG. Choi, SY. Jo, JY. Lee, HN. Im, GY. Lee, SJ. Chung (Seoul, Republic of Korea)

    Objective: To determine how Parkinson’s disease (PD) medications influence gut microbiome composition and function, and to distinguish microbiome features associated with PD pathology from those…
  • 2026 International Congress

    Pueraria tuberosa improves the locomotion defects in Drosophila model of FRDA

    R K. Yadav, D. Talukdar, V. Swarup, A. Ahuja, A. Srivastava, M. Aski, P. Yadav (New Delhi, India)

    Objective: To study the therapeutic potential of the medicinal herb Pueraria tuberosa on Drosophila model of Friedreich’s ataxia. Background: Reduced levels of the mitochondrial protein…
  • 2026 International Congress

    The Therapeutic Landscape of SSPE: A Systematic Review of Antiviral and Immunomodulatory Modalities

    V. Jadhav, S. Errabelly, M. Tripathi, D. Dash, P. Mohapatra, E. Arunmozhimaran (New Delhi, India)

    Objective: To systematically map the global therapeutic landscape of SSPE interventions, specifically characterizing drug regimens, dosages, administration routes, and monotherapy versus combination protocols. Background: SSPE…
  • 2026 International Congress

    Cerebellar Non-Invasive Brain Stimulation for Tremor Reduction in Essential Tremor: Systematic Review and Meta-Analysis of Randomized Controlled Trials

    A. Gunasekar, T. Lalotra, S. Nair, S. Khankar, N. K, R. Velusamy, A. Dey, R. Ramananthan, J. Srirangaramasamy, B. Kamaraj (Thiruvallur, India)

    Objective: To evaluate the safety and efficacy of cerebellar NIBS for tremor reduction inpatients with ET. Background: Essential tremor (ET) is generally managed pharmacologically, but…
  • 2026 International Congress

    Prevalence and characteristics of sleep disorders in Parkinson’s disease: an Argentine cohort.

    F. San Juan, F. Echeverria, S. Rodriguez, T. Arakaki, N. Garreto (CABA, Argentina)

    Objective: To evaluate the prevalence, severity, and clinical correlates of sleep disturbances in patients with Parkinson’s disease (PD) using validated sleep assessment scales and questionnaires.…
  • « Previous Page
  • 1
  • …
  • 90
  • 91
  • 92
  • 93
  • 94
  • …
  • 208
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley